Peer-reviewed veterinary case report
Blood microRNA patterns can predict survival in dogs with bone cancer
By Ludwig, Latasha et al.·Published in PloS one·2024·Department of Pathobiology, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Plasma microRNA signatures predict prognosis in canine osteosarcoma patients.
- Species:
- dog
Plain-English summary
A study found that dogs with a type of bone cancer called osteosarcoma often have a poor prognosis, especially if the cancer spreads to the lungs. Researchers looked at tiny molecules called microRNAs in the blood of these dogs to see if they could help predict outcomes. They discovered that a specific microRNA, miR-214-3p, was linked to worse survival rates. High levels of this microRNA indicated a shorter time before the disease progressed. This suggests that testing for miR-214-3p could help veterinarians better understand how a dog with osteosarcoma might respond to treatment.
People also search for: dog osteosarcoma prognosis · miR-214-3p in dogs · canine bone cancer treatment options
Abstract
Appendicular central osteosarcoma (OSA) is a common and highly aggressive tumour in dogs. Metastatic disease to the lungs is common and even with chemotherapy the prognosis is generally poor. However, few cases survive well beyond reported median survival times. Current methods, including histologic grading schemes, have fallen short in their ability to predict clinical outcome. MicroRNAs (miRNAs) are small molecules present in all tissues and bodily fluids and are dysregulated in cancer. Previous studies have demonstrated the diagnostic and prognostic potential of miRNAs in canine OSA. We sought to investigate multiple miRNA and multiple variable models for diagnosis and prognosis of canine OSA using plasma samples across three populations of dogs from two veterinary biobanks. Fifty-six miRNAs were analyzed by real-time quantitative polymerase chain reaction. MiR-214-3p was the only miRNA with increased expression across all OSA populations compared to controls. Using a decision tree model for diagnosis, miR-214-3p was the first step in this multi-miRNA model. High expression of miR-214-3p alone was also a predictor of shorter overall survival and disease-free interval across all populations. In both multiple miRNA and multiple variable models, miR-214-3p was always the first decision point with high expression consistently predicting a worse prognosis. Additional miRNAs in combination with low expression of miR-214-3p similarly had a worse prognosis demonstrating better outcome prediction using multiple miRNAs compared to using miR-214-3p alone. Multiple variable models only need to use miRNAs to be predictive although clinical parameters such as age, sex, and tumour location were considered. MiR-214-3p is clearly an important prognostic predictor of canine OSA in plasma as supported by previous studies and across our multiple sample populations. Multiple miRNA models provided superior categorization of patients in predicting clinical outcome parameters compared to the single miRNAs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39739708/